Human Genome Epidemiology Literature Finder
Pharmacogenomics
|
Records 1 - 30 (of 664 Records) |
| Query Trace: Gefitinib[original query] |
|---|
| Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs. Thoracic cancer 2023 9 . Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chua |
| Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence. Thoracic cancer 2023 9 . Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wa |
| Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023 9 . Thanyanan Reungwetwattana, Byoung Chul Cho, Ki Hyeong Lee, Yong Kek Pang, Chin Heng Fong, Jin Hyoung Kang, Yun-Gyoo Lee, Chun Sen Lim, Pongwut Danchaivijitr, Yueh Ni Lim, Youngjoo Lee, Soon Hin How, Sarayut Geater, Sung Sook Lee, Young Joo Min, Joo-Hang Kim, Jong-Seok Lee, Gyeong-Won Lee, Ross A Soo, Sae Young Lee, SeokYoung Choi, Myung-Ju A |
| A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced NSCLC patients. Translational lung cancer research 2023 8 12 (7): 1425-1435. In Ae Kim, Jae Young Hur, Hee Joung Kim, Wan Seop Kim, Kye Young L |
| Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset. Cancer research and treatment 2023 7 . Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Ka |
| Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO open 2023 7 8 (4): 101594. K Tamura, T Yoshida, K Masuda, Y Matsumoto, Y Shinno, Y Okuma, Y Goto, H Horinouchi, N Yamamoto, Y O |
| Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial. Cancer medicine 2023 6 . Masahiro Iwasaku, Junji Uchino, Kenji Chibana, Shigeru Tanzawa, Takahiro Yamada, Kazunori Tobino, Yasuki Uchida, Takashi Kijima, Katsumi Nakatomi, Miiru Izumi, Nobuyo Tamiya, Hideharu Kimura, Masaki Fujita, Ryoichi Honda, Chieko Takumi, Tadaaki Yamada, Yoshiko Kaneko, Fumiaki Kiyomi, Koichi Takaya |
| Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series. OncoTargets and therapy 2024 9 17 717-726. Kaoruko Shimbu, Kakeru Hisakane, Naohiro Kadoma, Shunichi Nishima, Kenichiro Atsumi, Masahiro Seike, Takashi Hiro |
| Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01. Targeted oncology 2024 9 . Makoto Hibino, Yoshinori Imamura, Rai Shimoyama, Tomoya Fukui, Ryuta Fukai, Akihiko Iwase, Yukihiro Tamura, Yusuke Chihara, Takafumi Okabe, Kiyoaki Uryu, Tadahisa Okuda, Masataka Taguri, Hironobu Mina |
| Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment. American journal of clinical oncology 2024 9 . Zaheer Qureshi, Faryal Altaf, Abdur Jamil, Rimsha Siddiq |
| Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Translational lung cancer research 2024 8 13 (7): 1649-1659. Mau Ern Poh, Sivasubramaniam Balakrishnan, Sin Nee Tan, Muhammad Adil Zainal Abidin, Chong Kin Liam, Jiunn Liang Tan, Yong Kek Pang, Arvindran Alaga, Lye Mun Tho, Soon Hin H |
| An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma. Discover oncology 2024 8 15 (1): 382. Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizusihima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Yasuaki Masaki, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Hirokazu Taniguchi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Minehiko Inoma |
| Analysis of the effect of baseline detection and early clearance of ct-DNA, on survival outcomes among patients with advanced EGFR-mutant non-small cell lung cancer. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2024 8 38 (1): 40-49. A Joel, R Abarna, R T Chacko, A Singh, J T Georgy, A O John, D B Thumaty, S Balukrishna, R Isiah, S Paavamani, T A Kodiatte, S Rima, G Rebekah, R P |
| Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis. Frontiers in oncology 2024 7 14 1354854. Xueming Xia, Wei Du, Yan Zhang, Yanying Li, Min Yu, Yongmei L |
| The Impact of Baseline Vitamin D Level in Patients Receiving Gefitinib-Directed Therapy for EGFR-Mutant Non-Small-Cell Lung Cancer. Clinical Medicine Insights. Oncology 2024 6 18 11795549241254460. Vanita Noronha, Manali Kolkur, R ArunKumar, Supriya Adak, Vijay Patil, Nandini Menon, Minit Shah, Kumar Prabha |
| Targeted analysis of Ubiquitin-Specific Peptidase (USP8) in a population of Iranian people with Cushing's disease and a systematic review of the literature. BMC endocrine disorders 2024 6 24 (1): 86. Nahid Hashemi-Madani, Sara Cheraghi, Zahra Emami, Ali Zare Mehrjardi, Mahmoud Reza Kaynama, Mohammad E Khams |
| First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. Expert review of anticancer therapy 2024 5 1-6. Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Choua |
| Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis. Genes 2024 5 15 (5): . Mariana Vieira Morau, Cecília Souto Seguin, Marília Berlofa Visacri, Eder de Carvalho Pincinato, Patricia Mori |
| Spheroids Generated from Malignant Pleural Effusion as a Tool to Predict the Response of Non-Small Cell Lung Cancer to Treatment. Diagnostics (Basel, Switzerland) 2024 5 14 (10): . Tsung-Ming Yang, Yu-Hung Fang, Chieh-Mo Lin, Miao-Fen Chen, Chun-Liang L |
| Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer. PloS one 2024 5 19 (5): e0303046. Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Ch |
| Holliday junction recognition protein (HJURP) could reflect the clinical outcomes of lung adenocarcinoma patients, and impact the choice of precision therapy. Frontiers in genetics 2024 12 15 1475511. Xixi Gao, Yingqing Zhang, Ming Zhang, Yuejiao S |
| EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment? Anticancer research 2024 12 45 (1): 335-340. Giuseppina Improta, Giulia Vita, Alfredo Tartarone, Giovanni Calice, Ludmila Carmen Omer, Angela Zu |
| Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis. Anticancer research 2024 12 44 (12): 5361-5370. Francisco Cezar Aquino DE Moraes, Maria Eduarda Cavalcanti Souza, Emanuele Rocha DA Silva, Michele Kreuz, Rommel Mario Rodriguez Burba |
| Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer. Journal of thoracic disease 2024 11 16 (10): 6579-6594. Zhifei Li, Hongyuan Chu, Sicheng Huang, Runze Li, Bin Qiu, Fengwei Tan, Qi Xue, Shugeng Gao, Jie |
| First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. BMC cancer 2024 10 24 (1): 1326. Yanjuan Xiong, Lu Wang, Weihong Zhang, Yuan Meng, Yang Wang, Meng Shen, Li Zhou, Runmei Li, Yingge Lv, Shengguang Wang, Xiubao Ren, Liang L |
| ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancers 2024 10 16 (20): . Ryo Kimura, Yuta Adachi, Kentaro Hirade, Satoru Kisoda, Shogo Yanase, Noriko Shibata, Makoto Ishii, Yutaka Fujiwara, Rui Yamaguchi, Yasuko Fujita, Waki Hosoda, Hiromichi E |
| Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors. The journal of pathology. Clinical research 2024 1 10 (2): e354. Michael Menzel, Martina Kirchner, Klaus Kluck, Markus Ball, Susanne Beck, Michael Allgäuer, Christin Assmann, Johannes Schnorbach, Anna-Lena Volckmar, Timothy Kwang Yong Tay, Hannah Goldschmid, Daniel Sw Tan, Michael Thomas, Daniel Kazdal, Jan Budczies, Albrecht Stenzinger, Petros Christopoul |
| Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 1 . Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiaoxu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xueding Wang, Li Zha |
| Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study. BMC cancer 2024 1 24 (1): 70. Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo She |
| Outcome of Epidermal Growth Factor Receptor Mutated and Non Mutated Adenocarcinoma Lung to Standard Therapy. Journal of Nepal Health Research Council 2024 1 21 (2): 330-335. Soniya Dulal, Akshat Mishra, Aarati Shah, Bibek Acharya, Ramila Shilpakar, Sandhya Chapagain Acharya, Ambuj Karn, Rajeev Sharma, Balram Gautam, Bishnu Dutta Paud |
- Page last reviewed:Feb 1, 2024
- Content source: